Agnieszka Potasiewicz Selected Research

Cognitive Dysfunction

1/2021	Repeated treatment with alpha 7 nicotinic acetylcholine receptor ligands enhances cognitive processes and stimulates Erk1/2 and Arc genes in rats.
1/2020	Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors enhance procognitive effects of conventional anti-Alzheimer drugs in scopolamine-treated rats.
1/2017	3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats.
1/2017	Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.
2/2016	Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats.
1/2016	The effects of PDE10 inhibition on attentional set-shifting do not depend on the activation of dopamine D1 receptors.
8/2015	Effects of the selective 5-HT7 receptor antagonist SB-269970 on premature responding in the five-choice serial reaction time test in rats.
5/2013	The 5-hydroxytryptamine (serotonin) receptor 6 agonist EMD 386088 ameliorates ketamine-induced deficits in attentional set shifting and novel object recognition, but not in the prepulse inhibition in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Agnieszka Potasiewicz Research Topics

Disease

9	Schizophrenia (Dementia Praecox) 01/2021 - 05/2013
8	Cognitive Dysfunction 01/2021 - 05/2013
3	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 10/2016
1	AIDS-Related Complex (ARC) 01/2021
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2021
1	Treatment-Resistant Depressive Disorder 10/2020
1	Memory Disorders (Memory Loss) 01/2020
1	Central Nervous System Diseases (CNS Diseases) 05/2013

Drug/Important Bio-Agent (IBA)

5	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2021 - 08/2015
5	Ketamine FDA LinkGeneric 10/2020 - 05/2013
2	1- (5- chloro- 2,4- dimethoxyphenyl)- 3- (5- methylisoxazol- 3- yl)ureaIBA 01/2021 - 01/2020
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2020 - 08/2015
2	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2020 - 10/2016
2	Memantine (Namenda)FDA Link 01/2020 - 10/2016
2	Serotonin (5 Hydroxytryptamine)IBA 08/2015 - 05/2013
1	LigandsIBA 01/2021
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	EsketamineIBA 10/2020
1	Donepezil (Aricept)FDA LinkGeneric 01/2020
1	Galantamine (Galanthamine)FDA LinkGeneric 01/2020
1	Methylazoxymethanol AcetateIBA 01/2020
1	NeurotoxinsIBA 01/2020
1	Scopolamine (Hyoscine)FDA Link 01/2020
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2020
1	Glutamic Acid (Glutamate)FDA Link 01/2020
1	metanicotineIBA 12/2018
1	Cholinergic ReceptorsIBA 12/2018
1	Varenicline (Chantix)FDA Link 12/2018
1	PNU-282987IBA 12/2018
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2017
1	Antipsychotic Agents (Antipsychotics)IBA 01/2017
1	positive allosteric modulator PAM-2IBA 01/2017
1	alpha7 Nicotinic Acetylcholine ReceptorIBA 01/2017
1	3-(2,4-dimethoxybenzylidene)anabaseineIBA 01/2017
1	SCH 23390IBA 01/2016
1	Dopamine D1 Receptors (Dopamine D1 Receptor)IBA 01/2016
1	serotonin 6 receptorIBA 05/2013

Therapy/Procedure

2	Therapeutics 01/2017 - 05/2013